ProMIS Neurosciences Inc. (PMN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $13.46 (+4.50%), Market cap $0.10B, 52-week low–high $0.29 ~ $24.79.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treati
Financial statements, price targets, institutional (13F) holdings and related news for ProMIS Neurosciences Inc. are updated in real time on BlackAll Trade.
ProMIS Neurosciences Inc. trades at $13.46 (+4.50%). Real-time quotes and charts are available on BlackAll Trade.
ProMIS Neurosciences Inc. has a market cap of about $0.10B.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary d